U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing